Media headlines about IRIDEX (NASDAQ:IRIX) have trended somewhat negative on Saturday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IRIDEX earned a news impact score of -0.01 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 44.3760790542064 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Separately, Zacks Investment Research upgraded IRIDEX from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th.
IRIDEX (NASDAQ IRIX) traded up $0.02 during mid-day trading on Friday, hitting $5.73. The stock had a trading volume of 58,936 shares, compared to its average volume of 34,375. IRIDEX has a 52 week low of $5.31 and a 52 week high of $14.19. The company has a market cap of $67.05, a price-to-earnings ratio of -5.16 and a beta of 1.37.
COPYRIGHT VIOLATION WARNING: “IRIDEX (IRIX) Earns Daily Coverage Optimism Rating of -0.01” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3253715/iridex-irix-earns-daily-coverage-optimism-rating-of-0-01.html.
IRIDEX Company Profile
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.